CHAPEL HILL, NC--(Marketwire - Feb 14, 2013) - Crown Marketing (OTCQB: CWNM) is pleased to announce that Patents for its Controlled Drug Delivery Technology have been approved and registered in South Africa. Crown is continuing to secure its worldwide patent rights as it pursues novel applications of its drug delivery technology
About The Company:
Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles of diffusion through precise mathematical formulas. The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. CDDT's simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.
The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.
Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.
More information can be found at: www.crowncddt.com
This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.